Limited Sampling Estimates of Epigallocatechin Gallate Exposures in Cirrhotic and Noncirrhotic Patients With Hepatitis C After Single Oral Doses of Green Tea Extract

Marzio, Dina Halegoua-De; Kraft, Walter K.; Daskalakis, Constantine; Xie, Yu; Hawke, Roy L.; Navarro, Victor J.

doi:10.1016/j.clinthera.2012.10.009

Cited by 23 publications

(15 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, in hepatocellular carcinoma, green tea did not have any protective effect [147] . In a study performed by Halegoua-De Marzio et al [148] they have shown, after a single oral dose of green tea (400 mg), in patients with cirrhosis induced by HCV, that it is safe and well tolerable by all patients, therefore suggesting the use of green tea in the treatment of cirrhosis in the future. However, more clinical studies related to the beneficial effects on liver diseases are needed.…”

Section: Green Teamentioning

confidence: 99%

Antioxidants in liver health

Casas‐Grajales

Muriel

2015

WJGPT

116

View full text Add to dashboard Cite

Liver diseases are a worldwide medical problem because the liver is the principal detoxifying organ and maintains metabolic homeostasis. The liver metabolizes various compounds that produce free radicals (FR). However, antioxidants scavenge FR and maintain the oxidative/antioxidative balance in the liver. When the liver oxidative/antioxidative balance is disrupted, the state is termed oxidative stress. Oxidative stress leads to deleterious processes in the liver and produces liver diseases. Therefore, restoring antioxidants is essential to maintain homeostasis. One method of restoring antioxidants is to consume natural compounds with antioxidant capacity. The objective of this review is to provide information pertaining to various antioxidants found in food that have demonstrated utility in improving liver diseases.

show abstract

Section: Green Teamentioning

confidence: 99%

Antioxidants in liver health

Casas‐Grajales

Muriel

2015

WJGPT

116

View full text Add to dashboard Cite

show abstract

“… 30 , 31 , 32 Additionally, limited sampling estimates of EGCG in HCV patients suggest that a single oral dose of up to 400 mg of this green tea extract is safe and well tolerated. 92 Additional experiments are needed to evaluate the possibility of using this compound as a candidate for anti-HCV therapy.…”

Section: Hcv Entry Into Hepatocytesmentioning

confidence: 99%

Entry inhibitors: New advances in HCV treatment

Qian

Zhu

Zhao

et al. 2016

Emerging Microbes & Infections

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection affects approximately 3% of the world's population and causes chronic liver diseases, including liver fibrosis, cirrhosis, and hepatocellular carcinoma. Although current antiviral therapy comprising direct-acting antivirals (DAAs) can achieve a quite satisfying sustained virological response (SVR) rate, it is still limited by viral resistance, long treatment duration, combined adverse reactions, and high costs. Moreover, the currently marketed antivirals fail to prevent graft reinfections in HCV patients who receive liver transplantations, probably due to the cell-to-cell transmission of the virus, which is also one of the main reasons behind treatment failure. HCV entry is a highly orchestrated process involving initial attachment and binding, post-binding interactions with host cell factors, internalization, and fusion between the virion and the host cell membrane. Together, these processes provide multiple novel and promising targets for antiviral therapy. Most entry inhibitors target host cell components with high genetic barriers and eliminate viral infection from the very beginning of the viral life cycle. In future, the addition of entry inhibitors to a combination of treatment regimens might optimize and widen the prevention and treatment of HCV infection. This review summarizes the molecular mechanisms and prospects of the current preclinical and clinical development of antiviral agents targeting HCV entry.

show abstract

“…Polyphenols extracted from green tea also exhibited potent activity against HCV viral entry [ 51 ] and replication [ 52 ]. In one study, a single oral administration of green tea extract containing 94% pure EGCG was safe and well-tolerated by all 11 patients with cirrhosis associated with chronic HCV infection [ 53 ].…”

Section: Potent Natural Products and Herbal Medicines For The Managemmentioning

confidence: 99%

Potent natural products and herbal medicines for treating liver fibrosis

Chen

et al. 2015

Chin Med

View full text Add to dashboard Cite

Liver fibrosis is a wound-healing response to chronic liver injury characterized by progressive inflammation and deposition of extracellular matrix components. The pathological condition of liver fibrosis involves secretion of extracellular matrix proteins and formation of scar tissue. The major regulators involved in hepatic fibrogenesis are the transforming growth factor (TGF)-β1/SMAD and toll-like receptor 4 (TLR4)-initiated myeloid differentiation primary response 88 gene (MyD88)/NF-ĸB cell signaling pathways. This article reviews natural products and herbal medicines that have demonstrated activity against liver fibrosis through different mechanisms of action, including anti-hepatitis B and C virus activity, anti-inflammation, inhibition of cytokine production and nuclear receptor activation, and free radical scavenging.

show abstract

Limited Sampling Estimates of Epigallocatechin Gallate Exposures in Cirrhotic and Noncirrhotic Patients With Hepatitis C After Single Oral Doses of Green Tea Extract

Cited by 23 publications

References 30 publications

Antioxidants in liver health

Antioxidants in liver health

Entry inhibitors: New advances in HCV treatment

Potent natural products and herbal medicines for treating liver fibrosis

Contact Info

Product

Resources

About